Adial completes AD04 demo batch, clearing path for planned Phase 3 trial

• Adial Pharmaceuticals completed manufacturing of a demonstration batch for its AD04 drug candidate, clearing a key step toward a planned Phase 3 clinical trial in Alcohol Use Disorder.
• Results have already been generated from the batch work, showing process performance consistent with prior Phase 2 production.
• The outcome supports production of clinical and registration batches, which Adial expects to use to advance trial execution and update its IND with FDA.
• Adial is planning a new Phase 3 program targeting patients selected with its proprietary genetic test, following earlier ONWARD findings that indicated potential benefit without new safety or tolerability concerns.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604220935PRIMZONEFULLFEED9694191) on April 22, 2026, and is solely responsible for the information contained therein.